

# May 2021 PDL/DUR Board Meeting Minutes

**Date:** May 26, 2021

**Members Present:** Anglim, Blake, King, McGrane, Caldwell, Nauts, Stone, Brown, Jost

**Members Absent:** Blank, Maxwell, Putsch

**Others Present:** Sexauer, Feist, Peterson, from DPHHS Montana Healthcare Programs; Kathy Novak from Magellan; Bahny, Barnhill, Doppler, Woodmansey, Artis and Opitz from Mountain-Pacific; various representatives from the pharmaceutical industry and the public.

**Public Comment:** The public had an opportunity to address the committee regarding non-agenda items and make other social comments. There were no comments.

**Meeting Minute Review:** Meeting minutes from April were approved as written.

**Department Update:** There was no Department update.

## PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2021 RECOMMENDATIONS	Grandfather
ANTICONVULSANTS	ND-Fintepla <sup>®</sup> , XCopri <sup>®</sup> NI-Epidiolex <sup>®</sup> , Vimpat <sup>®</sup> , levetiracetam	<p><b>Carbamazepine Derivatives-</b> Must have carbamazepine chewable, oral tablets and suspension, a long-acting carbamazepine, and oxcarbazepine immediate release. May add others.</p> <p><b>First Generation-</b> Must have phenobarbital, phenytoin, primidone, phenytoin 30mg and 50mg, Dilvalproex IR and ER, ethosuximide capsules and suspension, valproic acid caps and suspension. Do not add felbamate.</p> <p><i>Remove mephobarbital due to discontinuation in 2012 and being no longer available.</i></p> <p><b>Second Generation and Others-</b>Must have a rescue</p>	No

CLASS	DRUG NAME	2021 RECOMMENDATIONS	Grandfather
ANTICONVULSANTS (cont.)		product ( <i>with corresponding PA criteria to allow for appropriate access</i> ), gabapentin, lamotrigine, levetiracetam, pregabalin, topiramate IR, zonisamide, and lamotrigine starter pack. May add others.	No
ANTIPARKINSON'S AGENTS	ND-Ongentys <sup>®</sup> , Kynmobi <sup>®</sup> NI-Gocovri <sup>®</sup>	Must have a dopamine agonist, a COMT inhibitor, a MAO-B inhibitor, trihexyphenidyl, benzotropine, amantadine, IR carbidopa/levodopa, CR carbidopa/levodopa. May add others.	No
MULTIPLE SCLEROSIS AGENTS	ND-Bafiertam <sup>®</sup> , Kesimpta <sup>®</sup> , Zeposia <sup>®</sup> NI- Plegridy <sup>®</sup>	Must have glatiramer, one interferon agent, <i>and an oral agent</i> . May add others (excluding physician administered). Grandfathered class.	Yes
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR	ND-Eysuvis <sup>®</sup>	Therapeutic alternatives. May add with PA criteria for appropriate use.	No
SEDATIVE HYPNOTICS	ND-Dayvigo <sup>®</sup> NI-Hetlioz <sup>®</sup>	Therapeutic alternatives. <b>Benzodiazepines:</b> Must have temazepam, do not add others. <b>BZ-1 selective agents:</b> Must have 1 BZ-1 selective agent. May add others. Do not add ramelteon. <i>Remove "Continue Belsomra<sup>®</sup> clinical criteria". This <b>will not</b> remove the clinical criteria requirement for the medication. It will only remove mention of the previous recommendation.</i>	No

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics and discontinued items in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2020 were retained. They are as follows:

CLASS	2021 RECOMMENDATIONS	Grandfather
ALZHEIMER'S AGENTS	Must have donepezil; may add others. Continue PA criteria on memantine products. Grandfathered class.	Yes
ANALGESICS, NARCOTIC LONG ACTING	Must have one-long acting formulation of morphine or oxycodone; Must have buprenorphine transdermal formulation. May add others. Continue clinical criteria. Grandfathered class.	Yes
ANTIDEPRESSANTS, OTHERS	Must have bupropion XL, trazodone, mirtazapine, venlafaxine ER. May add others. Grandfathered class.	Yes
ANTIDEPRESSANTS, SSRI'S	Class effect. Must have a diagnosis of VMS associated with menopause for Brisdelle®. Grandfathered class.	Yes
ANTIMIGRAINE AGENTS	Must have 1 nasal formulation, 1 injection, and 1 short acting agent (short-acting agents have class effect); May add others.	No
ANTIPSYCHOTICS, ATYPICAL	Must have aripiprazole, risperidone, quetiapine, olanzapine, ziprasidone, lurasidone and clozapine. May add others. Continue clinical criteria. Grandfathered class.	Yes
MOVEMENT DISORDERS	May add with PA criteria.	No

CLASS	2021 RECOMMENDATIONS	Grandfather
NEUROPATHIC PAIN	Must have duloxetine and gabapentin. May add others. Continue existing specific PA criteria. Grandfathered class.	Yes
NSAIDS	Class effect. Must have one oral and one topical agent.	No
OPHTHALMIC ALLERGIC CONJUNCTIVITIS	<b>Antihistamines</b> - Class effect. <b>Mast Cell Stabilizers</b> – Class effect.	No
OPHTHALMIC ANTIBIOTICS	Class effect.	No
OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS	Class effect.	No
OPHTHALMICS, ANTI-INFLAMMATORIES	<b>NSAIDS</b> - Class effect. <b>Steroids</b> - Therapeutic alternatives.	No
OPHTHALMIC GLAUCOMA AGENTS	<b>OPHTHALMIC ALPHA 2 ADRENERGIC AGENTS</b> : Must have brimonidine due to increased efficacy; May add others. <b>OPHTHALMIC BETA BLOCKERS</b> : Class effect. <b>OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS/RHO KINASE INHIBITORS</b> : Must have one single agent; May add others. <b>OPHTHALMIC PROSTAGLANDINS</b> : Class effect.	No
OTIC ANTIBIOTICS & COMBOS	Class effect.	No
OTIC ANTI-INFECTIVES & ANESTHETICS	Therapeutic alternatives.	No

CLASS	2021 RECOMMENDATIONS	Grandfather
OTICS, ANTI-INFLAMMATORY	May add.	No
SKELETAL MUSCLE RELAXANTS	Must have baclofen and cyclobenzaprine; other agents are therapeutic alternatives.	No
STIMULANTS & RELATED AGENTS	<p><b>Non-Stimulant ADHD agents</b>-Must have atomoxetine. May add other nonstimulants. Continue criteria on clonidine ER and only one preferred agent trial is required.</p> <p><i>Requested that clonidine ER criteria be rereviewed at future DUR meeting.</i></p> <p><b>Stimulants</b>-Trial of 2 preferred agents required; Must have one long acting agent and one short-acting agent each of a methylphenidate-like product and an amphetamine-like product. May add others. Grandfathered class, only applies to stimulants.</p>	<p>Non-Stimulants-No</p> <p>Stimulants-Yes</p>

CLASS	2021 RECOMMENDATIONS	Grandfather
ANTIHYPERTENSIVES, SYMPATHOLYTICS	Therapeutic alternatives; Must have a clonidine product and a guanfacine product; May add others.	No
SUBSTANCE USE DISORDER TREATMENTS	<p><b>Opioid Use Disorder Treatments</b>-Therapeutic alternatives. Must have buprenorphine/naloxone film. Do not add buprenorphine monotherapy tablet or buprenorphine/naloxone tablet.</p> <p><b>Opioid Reversal</b>-Must have injection and nasal naloxone.</p>	No

There were no Group 1 agents (green category) to review at this time.

Tony King ended the meeting with a reminder of the next DUR Board meeting being scheduled for July 21, 2021 in this same format. Meeting adjourned 2:30pm.